Large Outflow of Money Witnessed in Pfizer

Pfizer (PFE) :The total money flow, which is calculated as the dollar value of composite uptick minus downtick trades was negative ($21 million) and the uptick to downtick ratio was 0.77. The transaction value on upticks was $69.71 million and on downticks, the transaction value was $90.71 million. In block trades, the transaction value of inflow done during uptick was $1.96 million. The transaction value of block trades during downticks was $20.35 million. The uptick to downtick block trade ratio was 0.1. The money flow was negative ($18.39 million), indicating the traders were booking profit on the price strength. Pfizer (PFE) rose $0.08 at $36.23, during intraday Tuesday , a rise of 0.22% over the previous days close.


The company Insiders own 0.07% of Pfizer shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -18.54% . Institutional Investors own 75.07% of Pfizer shares. During last six month period, the net percent change held by insiders has seen a change of -18.54%. In an insider trading activity,The officer (Executive Vice President) of Pfizer Inc, Damelio Frank A sold 100,000 shares at $34.49 on May 26, 2016. The Insider selling transaction had a total value worth of $3,449,000. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Shares of Pfizer Inc. rose by 1.2% in the last five trading days and 2.69% for the last 4 weeks. Pfizer Inc. is up 14.41% in the last 3-month period. Year-to-Date the stock performance stands at 14.41%.

Pfizer (NYSE:PFE): stock turned positive on Tuesday. Though the stock opened at $36.15, the bulls momentum made the stock top out at $36.3 level for the day. The stock recorded a low of $36.03 and closed the trading day at $36.24, in the green by 0.25%. The total traded volume for the day was 16,192,018. The stock had closed at $36.15 in the previous days trading.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and womens/mens health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.